Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079704328> ?p ?o ?g. }
Showing items 1 to 59 of
59
with 100 items per page.
- W2079704328 endingPage "82" @default.
- W2079704328 startingPage "82" @default.
- W2079704328 abstract "Tuominen HJ, Tiihonen J, Wahlbeck K. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr Res 2005;72:225–34.[OpenUrl][1][CrossRef][2][PubMed][3][Web of Science][4] Q Are glutamate receptor agonist drugs effective for people with schizophrenia? ### ![Graphic][5]</img>Design: Systematic review with meta-analysis. ### ![Graphic][6]</img>Data sources: Studies were identified using the Cochrane schizophrenia group’s trial register, BIOSIS Inside, CENTRAL, CINAHL, EMBASE, MEDLINE, and PsycINFO plus handsearches and contact with investigators. ### ![Graphic][7]</img>Study selection and analysis: Eligible studies were double blind randomised controlled trials (RCTs) of NMDA, AMPA, or kainate glutamate receptor agonist (glutamatergic) drugs in people with schizophrenia, with a trial duration of more than two weeks. Random and fixed effect models were used to carry out meta-analyses. ### ![Graphic][8]</img>Outcomes: Global response (Clinical Global Impression scale (CGI); Global Assessment Scale (GAS)), negative symptoms (Positive and Negative Syndrome Scale (PANSS); Scale for Assessment of Negative Symptoms), and cognitive deficiencies (PANSS cognitive subscale). Eighteen RCTs met inclusion criteria. The glutamatergic drugs investigated were D-cyloserine (7 RCTs), glycine (7 RCTs), … [1]: {openurl}?query=rft.jtitle%253DSchizophrenia%2Bresearch%26rft.stitle%253DSchizophr%2BRes%26rft.aulast%253DTuominen%26rft.auinit1%253DH.%2BJ.%26rft.volume%253D72%26rft.issue%253D2-3%26rft.spage%253D225%26rft.epage%253D234%26rft.atitle%253DGlutamatergic%2Bdrugs%2Bfor%2Bschizophrenia%253A%2Ba%2Bsystematic%2Breview%2Band%2Bmeta-analysis.%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.schres.2004.05.005%26rft_id%253Dinfo%253Apmid%252F15560967%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx [2]: /lookup/external-ref?access_num=10.1016/j.schres.2004.05.005&link_type=DOI [3]: /lookup/external-ref?access_num=15560967&link_type=MED&atom=%2Febmental%2F8%2F3%2F82.atom [4]: /lookup/external-ref?access_num=000226430200014&link_type=ISI [5]: /embed/inline-graphic-1.gif [6]: /embed/inline-graphic-2.gif [7]: /embed/inline-graphic-3.gif [8]: /embed/inline-graphic-4.gif" @default.
- W2079704328 created "2016-06-24" @default.
- W2079704328 creator A5024580674 @default.
- W2079704328 creator A5032024974 @default.
- W2079704328 date "2005-08-01" @default.
- W2079704328 modified "2023-10-05" @default.
- W2079704328 title "Glycine and D-serine improve the negative symptoms of schizophrenia" @default.
- W2079704328 cites W2037395811 @default.
- W2079704328 cites W2105454368 @default.
- W2079704328 cites W2141673227 @default.
- W2079704328 doi "https://doi.org/10.1136/ebmh.8.3.82" @default.
- W2079704328 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16043624" @default.
- W2079704328 hasPublicationYear "2005" @default.
- W2079704328 type Work @default.
- W2079704328 sameAs 2079704328 @default.
- W2079704328 citedByCount "7" @default.
- W2079704328 countsByYear W20797043282015 @default.
- W2079704328 countsByYear W20797043282018 @default.
- W2079704328 countsByYear W20797043282019 @default.
- W2079704328 crossrefType "journal-article" @default.
- W2079704328 hasAuthorship W2079704328A5024580674 @default.
- W2079704328 hasAuthorship W2079704328A5032024974 @default.
- W2079704328 hasBestOaLocation W20797043281 @default.
- W2079704328 hasConcept C118552586 @default.
- W2079704328 hasConcept C126322002 @default.
- W2079704328 hasConcept C168563851 @default.
- W2079704328 hasConcept C2776412080 @default.
- W2079704328 hasConcept C2779727114 @default.
- W2079704328 hasConcept C2780135775 @default.
- W2079704328 hasConcept C71924100 @default.
- W2079704328 hasConceptScore W2079704328C118552586 @default.
- W2079704328 hasConceptScore W2079704328C126322002 @default.
- W2079704328 hasConceptScore W2079704328C168563851 @default.
- W2079704328 hasConceptScore W2079704328C2776412080 @default.
- W2079704328 hasConceptScore W2079704328C2779727114 @default.
- W2079704328 hasConceptScore W2079704328C2780135775 @default.
- W2079704328 hasConceptScore W2079704328C71924100 @default.
- W2079704328 hasIssue "3" @default.
- W2079704328 hasLocation W20797043281 @default.
- W2079704328 hasLocation W20797043282 @default.
- W2079704328 hasOpenAccess W2079704328 @default.
- W2079704328 hasPrimaryLocation W20797043281 @default.
- W2079704328 hasRelatedWork W2044979734 @default.
- W2079704328 hasRelatedWork W2097994973 @default.
- W2079704328 hasRelatedWork W2516884906 @default.
- W2079704328 hasRelatedWork W2618232408 @default.
- W2079704328 hasRelatedWork W3159250744 @default.
- W2079704328 hasRelatedWork W4256514411 @default.
- W2079704328 hasRelatedWork W4292236216 @default.
- W2079704328 hasRelatedWork W4300411281 @default.
- W2079704328 hasRelatedWork W4386459847 @default.
- W2079704328 hasRelatedWork W2083697902 @default.
- W2079704328 hasVolume "8" @default.
- W2079704328 isParatext "false" @default.
- W2079704328 isRetracted "false" @default.
- W2079704328 magId "2079704328" @default.
- W2079704328 workType "article" @default.
!["Tuominen HJ, Tiihonen J, Wahlbeck K. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr Res 2005;72:225–34.[OpenUrl][1][CrossRef][2][PubMed][3][Web of Science][4] Q Are glutamate receptor agonist drugs effective for people with schizophrenia? ### ![Graphic][5]</img>Design: Systematic review with meta-analysis. ### ![Graphic][6]</img>Data sources: Studies were identified using the Cochrane schizophrenia group’s trial register, BIOSIS Inside, CENTRAL, CINAHL, EMBASE, MEDLINE, and PsycINFO plus handsearches and contact with investigators. ### ![Graphic][7]</img>Study selection and analysis: Eligible studies were double blind randomised controlled trials (RCTs) of NMDA, AMPA, or kainate glutamate receptor agonist (glutamatergic) drugs in people with schizophrenia, with a trial duration of more than two weeks. Random and fixed effect models were used to carry out meta-analyses. ### ![Graphic][8]</img>Outcomes: Global response (Clinical Global Impression scale (CGI); Global Assessment Scale (GAS)), negative symptoms (Positive and Negative Syndrome Scale (PANSS); Scale for Assessment of Negative Symptoms), and cognitive deficiencies (PANSS cognitive subscale). Eighteen RCTs met inclusion criteria. The glutamatergic drugs investigated were D-cyloserine (7 RCTs), glycine (7 RCTs), … [1]: {openurl}?query=rft.jtitle%253DSchizophrenia%2Bresearch%26rft.stitle%253DSchizophr%2BRes%26rft.aulast%253DTuominen%26rft.auinit1%253DH.%2BJ.%26rft.volume%253D72%26rft.issue%253D2-3%26rft.spage%253D225%26rft.epage%253D234%26rft.atitle%253DGlutamatergic%2Bdrugs%2Bfor%2Bschizophrenia%253A%2Ba%2Bsystematic%2Breview%2Band%2Bmeta-analysis.%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.schres.2004.05.005%26rft_id%253Dinfo%253Apmid%252F15560967%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx [2]: /lookup/external-ref?access_num=10.1016/j.schres.2004.05.005&link_type=DOI [3]: /lookup/external-ref?access_num=15560967&link_type=MED&atom=%2Febmental%2F8%2F3%2F82.atom [4]: /lookup/external-ref?access_num=000226430200014&link_type=ISI [5]: /embed/inline-graphic-1.gif [6]: /embed/inline-graphic-2.gif [7]: /embed/inline-graphic-3.gif [8]: /embed/inline-graphic-4.gif"](?object=%22Tuominen%20HJ%2C%20Tiihonen%20J%2C%20Wahlbeck%20K.%20Glutamatergic%20drugs%20for%20schizophrenia%3A%20a%20systematic%20review%20and%20meta-analysis.%20Schizophr%20Res%202005%3B72%3A225%E2%80%9334.%5BOpenUrl%5D%5B1%5D%5BCrossRef%5D%5B2%5D%5BPubMed%5D%5B3%5D%5BWeb%20of%20Science%5D%5B4%5D%20Q%20Are%20glutamate%20receptor%20agonist%20drugs%20effective%20for%20people%20with%20schizophrenia%3F%20%23%23%23%20!%5BGraphic%5D%5B5%5D%3C%2Fimg%3EDesign%3A%20Systematic%20review%20with%20meta-analysis.%20%23%23%23%20!%5BGraphic%5D%5B6%5D%3C%2Fimg%3EData%20sources%3A%20Studies%20were%20identified%20using%20the%20Cochrane%20schizophrenia%20group%E2%80%99s%20trial%20register%2C%20BIOSIS%20Inside%2C%20CENTRAL%2C%20CINAHL%2C%20EMBASE%2C%20MEDLINE%2C%20and%20PsycINFO%20plus%20handsearches%20and%20contact%20with%20investigators.%20%23%23%23%20!%5BGraphic%5D%5B7%5D%3C%2Fimg%3EStudy%20selection%20and%20analysis%3A%20Eligible%20studies%20were%20double%20blind%20randomised%20controlled%20trials%20(RCTs)%20of%20NMDA%2C%20AMPA%2C%20or%20kainate%20glutamate%20receptor%20agonist%20(glutamatergic)%20drugs%20in%20people%20with%20schizophrenia%2C%20with%20a%20trial%20duration%20of%20more%20than%20two%20weeks.%20Random%20and%20fixed%20effect%20models%20were%20used%20to%20carry%20out%20meta-analyses.%20%23%23%23%20!%5BGraphic%5D%5B8%5D%3C%2Fimg%3EOutcomes%3A%20Global%20response%20(Clinical%20Global%20Impression%20scale%20(CGI)%3B%20Global%20Assessment%20Scale%20(GAS))%2C%20negative%20symptoms%20(Positive%20and%20Negative%20Syndrome%20Scale%20(PANSS)%3B%20Scale%20for%20Assessment%20of%20Negative%20Symptoms)%2C%20and%20cognitive%20deficiencies%20(PANSS%20cognitive%20subscale).%20Eighteen%20RCTs%20met%20inclusion%20criteria.%20The%20glutamatergic%20drugs%20investigated%20were%20D-cyloserine%20(7%20RCTs)%2C%20glycine%20(7%20RCTs)%2C%20%E2%80%A6%20%5B1%5D%3A%20%7Bopenurl%7D%3Fquery%3Drft.jtitle%25253DSchizophrenia%252Bresearch%2526rft.stitle%25253DSchizophr%252BRes%2526rft.aulast%25253DTuominen%2526rft.auinit1%25253DH.%252BJ.%2526rft.volume%25253D72%2526rft.issue%25253D2-3%2526rft.spage%25253D225%2526rft.epage%25253D234%2526rft.atitle%25253DGlutamatergic%252Bdrugs%252Bfor%252Bschizophrenia%25253A%252Ba%252Bsystematic%252Breview%252Band%252Bmeta-analysis.%2526rft_id%25253Dinfo%25253Adoi%25252F10.1016%25252Fj.schres.2004.05.005%2526rft_id%25253Dinfo%25253Apmid%25252F15560967%2526rft.genre%25253Darticle%2526rft_val_fmt%25253Dinfo%25253Aofi%25252Ffmt%25253Akev%25253Amtx%25253Ajournal%2526ctx_ver%25253DZ39.88-2004%2526url_ver%25253DZ39.88-2004%2526url_ctx_fmt%25253Dinfo%25253Aofi%25252Ffmt%25253Akev%25253Amtx%25253Actx%20%5B2%5D%3A%20%2Flookup%2Fexternal-ref%3Faccess_num%3D10.1016%2Fj.schres.2004.05.005%26link_type%3DDOI%20%5B3%5D%3A%20%2Flookup%2Fexternal-ref%3Faccess_num%3D15560967%26link_type%3DMED%26atom%3D%252Febmental%252F8%252F3%252F82.atom%20%5B4%5D%3A%20%2Flookup%2Fexternal-ref%3Faccess_num%3D000226430200014%26link_type%3DISI%20%5B5%5D%3A%20%2Fembed%2Finline-graphic-1.gif%20%5B6%5D%3A%20%2Fembed%2Finline-graphic-2.gif%20%5B7%5D%3A%20%2Fembed%2Finline-graphic-3.gif%20%5B8%5D%3A%20%2Fembed%2Finline-graphic-4.gif%22){kind=link}